126 related articles for article (PubMed ID: 28011984)
1. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
2. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman SD; Thomas A; Thomas I; Hills RK; Vyas P; Gilkes A; Metzner M; Jakobsen NA; Kennedy A; Moore R; Almuina NM; Burns S; King S; Andrew G; Gallagher KME; Sellar RS; Cahalin P; Weber D; Dennis M; Mehta P; Knapper S; Russell NH
Blood; 2023 Nov; 142(20):1697-1707. PubMed ID: 37595359
[TBL] [Abstract][Full Text] [Related]
3. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract][Full Text] [Related]
4. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y;
Int J Hematol; 2024 Jun; 119(6):647-659. PubMed ID: 38532078
[TBL] [Abstract][Full Text] [Related]
7. The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.
Huang HH; Chen CM; Wang CY; Hsu WW; Chen HM; Ko BS; Hsiao FY
PLoS One; 2022; 17(1):e0261871. PubMed ID: 35061709
[TBL] [Abstract][Full Text] [Related]
8. How I treat relapsed or refractory AML.
DeWolf S; Tallman MS
Blood; 2020 Aug; 136(9):1023-1032. PubMed ID: 32518943
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia presenting as erythema nodosum: A case report.
Xu X; Liang G; Duan M; Zhang L
Medicine (Baltimore); 2017 Nov; 96(47):e8666. PubMed ID: 29381943
[TBL] [Abstract][Full Text] [Related]
10. How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Tiong IS; Wall M; Bajel A; Kalro A; Fleming S; Roberts AW; Thiagarajah N; Chua CC; Latimer M; Yeung D; Marlton P; Johnston A; Enjeti A; Fong CY; Cull G; Larsen S; Kennedy G; Schwarer A; Kipp D; Ramanathan S; Verner E; Tiley C; Morris E; Hahn U; Moore J; Taper J; Purtill D; Warburton P; Stevenson W; Murphy N; Tan P; Beligaswatte A; Mutsando H; Hertzberg M; Shortt J; Szabo F; Dunne K; Wei AH;
Blood Cancer J; 2024 Mar; 14(1):54. PubMed ID: 38531863
[TBL] [Abstract][Full Text] [Related]
11. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
Renga G; Nunzi E; Stincardini C; Pariano M; Puccetti M; Pieraccini G; Di Serio C; Fraziano M; Poerio N; Oikonomou V; Mosci P; Garaci E; Fianchi L; Pagano L; Romani L
Blood; 2024 Apr; 143(16):1628-1645. PubMed ID: 38227935
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual.
Yeoh K; Lass-Flörl C; Lamoth F; Slavin MA; Williams E; Neofytos D
Transpl Infect Dis; 2024 May; ():e14273. PubMed ID: 38695847
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S; Najima Y; Sadato D; Hirama C; Kishida Y; Nagata A; Konishi T; Yamada Y; Kurosawa S; Yoshifuji K; Shirane S; Shingai N; Toya T; Shimizu H; Haraguchi K; Kobayashi T; Harada H; Okuyama Y; Harada Y; Doki N
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38783125
[TBL] [Abstract][Full Text] [Related]
14. Krüppel-like factor 4 promotes survival and expansion in acute myeloid leukemia cells.
Lewis AH; Bridges CS; Punia VS; Cooper AFJ; Puppi M; Lacorazza HD
Oncotarget; 2021 Feb; 12(4):255-267. PubMed ID: 33659038
[TBL] [Abstract][Full Text] [Related]
15. Transplant without salvage: cut out the middleman.
Law AD; Mattsson JI
Lancet Haematol; 2024 May; 11(5):e310-e311. PubMed ID: 38583456
[No Abstract] [Full Text] [Related]
16. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M; Weber D; Döhner K; Krauter J; Gaidzik VI; Paschka P; Heuser M; Thol F; Kindler T; Lübbert M; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Köhne CH; Ringhoffer M; Wulf G; Held G; Salwender H; Benner A; Ganser A; Döhner H; Schlenk RF
Leukemia; 2017 Jun; 31(6):1306-1313. PubMed ID: 28138160
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD; Gale RP; Walter RB
Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin for acute myeloid leukemia.
Appelbaum FR; Bernstein ID
Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
[TBL] [Abstract][Full Text] [Related]
20. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.
Brandwein JM; Zhu N; Kumar R; Leber B; Sabloff M; Sandhu I; Kassis J; Olney HJ; Elemary M; Schuh AC
Am J Blood Res; 2017; 7(4):30-40. PubMed ID: 28804680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
